Clearmind announces publication of patent for binge behavior treatment

Clearmind Medicine (CMND) announced a patent publication by the Instituto Mexicano de la Propriedad Industrial, the National Mexico Patent Office. The patent refers to the Company’s combination therapy of MEAI and N-Acylethanolamines, addressing binge behavior, including alcohol consumption, eating, tobacco consumption, shopping and sexual conduct. The patent is part of Clearmind’s collaboration with SciSparc (SPRC). Together, the two companies are researching combination therapies that integrate psychedelic compounds with the N-Acylethanolamines family, including Palmitoylethanolamide.